← Eichor
Condition: Acute Myeloid Leukemia Adult Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Acute Myeloid Leukemia Adult

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06232694A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With A
Phase 2 · 19 location(s) · Shanghai Tong Ren Hospital · NCT05736965VA vs DA for Newly Diagnosed Hig-risk AML
Phase 2/Phase 3 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT05939180Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07490288A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensi
Phase N/A · 13 location(s) · AbbVie · NCT05317494Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Mye
NA · 1 location(s) · Fred Hutchinson Cancer Center · NCT07094750Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Pat
Phase 3 · 43 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT07223814Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Terrence J Bradley, MD · NCT05597306Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Phase 1 · 2 location(s) · Remedy Plan, Inc. · NCT07107126Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Ne
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06532552Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 7 location(s) · Nerviano Medical Sciences · NCT06549790OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
Phase N/A · 21 location(s) · French Innovative Leukemia Organisation · NCT06377579DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML
Phase 3 · 1 location(s) · The Second Affiliated Hospital of Kunming Medical University · NCT07712848A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leuk
Phase 2 · 32 location(s) · Stemline Therapeutics, Inc. · NCT06456463Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible
Phase N/A · 42 location(s) · French Innovative Leukemia Organisation · NCT06263387Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 2 location(s) · iCell Gene Therapeutics · NCT07668557Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Pacylex Pharmaceuticals · NCT06613217Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Trea
Phase 2 · 227 location(s) · National Cancer Institute (NCI) · NCT06317649CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relap
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04375631Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Phase 3 · 48 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04168502Relation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX)
Phase N/A · 1 location(s) · University Hospital, Caen · NCT06045819Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
Phase 1/Phase 2 · 1 location(s) · Sunshine Lake Pharma Co., Ltd. · NCT05133882A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in
Phase 2 · 20 location(s) · French Innovative Leukemia Organisation · NCT06022003Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Yo
Phase 2/Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT06756152Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-
Phase 3 · 91 location(s) · University of Ulm · NCT04628026Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1 · 5 location(s) · Tr1X, Inc. · NCT06462365A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Phase 1 · 3 location(s) · Cullgen (Shanghai),Inc · NCT07347171
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.